Cargando…

Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study

INTRODUCTION: The BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna) vaccines have been approved for children and adolescents for protecting against SARS-CoV-2 infection. This longitudinal study aimed to compare adverse outcomes after SARS-CoV-2 vaccination in children with neurodevelopmental disord...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Liang-Jen, Tsai, Ching-Shu, Chou, Wen-Jiun, Li, Chia-Jung, Lee, Sheng-Yu, Chen, Yi-Chun, Lin, I-Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225977/
https://www.ncbi.nlm.nih.gov/pubmed/37271705
http://dx.doi.org/10.1016/j.vaccine.2023.05.067
_version_ 1785050489751076864
author Wang, Liang-Jen
Tsai, Ching-Shu
Chou, Wen-Jiun
Li, Chia-Jung
Lee, Sheng-Yu
Chen, Yi-Chun
Lin, I-Chun
author_facet Wang, Liang-Jen
Tsai, Ching-Shu
Chou, Wen-Jiun
Li, Chia-Jung
Lee, Sheng-Yu
Chen, Yi-Chun
Lin, I-Chun
author_sort Wang, Liang-Jen
collection PubMed
description INTRODUCTION: The BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna) vaccines have been approved for children and adolescents for protecting against SARS-CoV-2 infection. This longitudinal study aimed to compare adverse outcomes after SARS-CoV-2 vaccination in children with neurodevelopmental disorders (ND) (e.g., attention-deficit/hyperactivity disorder [ADHD], autism spectrum disorder [ASD], communication disorders, intellectual disability, and tic disorders) and healthy control children. METHODS: A total of 1335 children who received the SARS-CoV-2 vaccination (762 children with ND and 573 healthy controls) were recruited. All subjects were followed-up for 180 days, and outcome events were defined as outpatient department (OPD) or emergency department (ER) visits during follow-up. Multivariate Cox proportional hazards regression models were used to identify the potential differences in outcomes between the propensity score-matched ND group (n = 311) and the control group (n = 311), and to explore the factors associated with outcomes among all children with ND (n = 762). RESULTS: Compared with the control group, children with ND exhibited a higher likelihood of subsequent OPD or ER visits and paediatric neurology OPD visits after the first dose of vaccination. However, we found that only a small proportion of the children visited the OPD or ER because of adverse vaccination-related effects. Among all children with ND, those with communication disorders showed a higher likelihood of any OPD or ER visit. Paediatric neurology OPD visits were associated with communication disorders, intellectual disability, and methylphenidate and aripiprazole prescriptions. ADHD and ASD were not associated with adverse outcomes. CONCLUSIONS: No specific ND diagnosis or medication use clearly increased the risk of adverse effects of SARS-CoV-2 vaccination. Children with ND can be reassured that the SARS-CoV-2 vaccination is a safe regimen to protect themselves.
format Online
Article
Text
id pubmed-10225977
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-102259772023-05-30 Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study Wang, Liang-Jen Tsai, Ching-Shu Chou, Wen-Jiun Li, Chia-Jung Lee, Sheng-Yu Chen, Yi-Chun Lin, I-Chun Vaccine Article INTRODUCTION: The BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna) vaccines have been approved for children and adolescents for protecting against SARS-CoV-2 infection. This longitudinal study aimed to compare adverse outcomes after SARS-CoV-2 vaccination in children with neurodevelopmental disorders (ND) (e.g., attention-deficit/hyperactivity disorder [ADHD], autism spectrum disorder [ASD], communication disorders, intellectual disability, and tic disorders) and healthy control children. METHODS: A total of 1335 children who received the SARS-CoV-2 vaccination (762 children with ND and 573 healthy controls) were recruited. All subjects were followed-up for 180 days, and outcome events were defined as outpatient department (OPD) or emergency department (ER) visits during follow-up. Multivariate Cox proportional hazards regression models were used to identify the potential differences in outcomes between the propensity score-matched ND group (n = 311) and the control group (n = 311), and to explore the factors associated with outcomes among all children with ND (n = 762). RESULTS: Compared with the control group, children with ND exhibited a higher likelihood of subsequent OPD or ER visits and paediatric neurology OPD visits after the first dose of vaccination. However, we found that only a small proportion of the children visited the OPD or ER because of adverse vaccination-related effects. Among all children with ND, those with communication disorders showed a higher likelihood of any OPD or ER visit. Paediatric neurology OPD visits were associated with communication disorders, intellectual disability, and methylphenidate and aripiprazole prescriptions. ADHD and ASD were not associated with adverse outcomes. CONCLUSIONS: No specific ND diagnosis or medication use clearly increased the risk of adverse effects of SARS-CoV-2 vaccination. Children with ND can be reassured that the SARS-CoV-2 vaccination is a safe regimen to protect themselves. Elsevier Ltd. 2023-06-29 2023-05-29 /pmc/articles/PMC10225977/ /pubmed/37271705 http://dx.doi.org/10.1016/j.vaccine.2023.05.067 Text en © 2023 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Wang, Liang-Jen
Tsai, Ching-Shu
Chou, Wen-Jiun
Li, Chia-Jung
Lee, Sheng-Yu
Chen, Yi-Chun
Lin, I-Chun
Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study
title Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study
title_full Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study
title_fullStr Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study
title_full_unstemmed Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study
title_short Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study
title_sort medical outcomes of children with neurodevelopmental disorders after sars-cov-2 vaccination: a six-month follow-up study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225977/
https://www.ncbi.nlm.nih.gov/pubmed/37271705
http://dx.doi.org/10.1016/j.vaccine.2023.05.067
work_keys_str_mv AT wangliangjen medicaloutcomesofchildrenwithneurodevelopmentaldisordersaftersarscov2vaccinationasixmonthfollowupstudy
AT tsaichingshu medicaloutcomesofchildrenwithneurodevelopmentaldisordersaftersarscov2vaccinationasixmonthfollowupstudy
AT chouwenjiun medicaloutcomesofchildrenwithneurodevelopmentaldisordersaftersarscov2vaccinationasixmonthfollowupstudy
AT lichiajung medicaloutcomesofchildrenwithneurodevelopmentaldisordersaftersarscov2vaccinationasixmonthfollowupstudy
AT leeshengyu medicaloutcomesofchildrenwithneurodevelopmentaldisordersaftersarscov2vaccinationasixmonthfollowupstudy
AT chenyichun medicaloutcomesofchildrenwithneurodevelopmentaldisordersaftersarscov2vaccinationasixmonthfollowupstudy
AT linichun medicaloutcomesofchildrenwithneurodevelopmentaldisordersaftersarscov2vaccinationasixmonthfollowupstudy